Natalie R. Hamilton

Natalie R. Hamilton

Auto-generated profile, based on publicly available information

Natalie R. Hamilton

Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 January 2022 in Cell
Verified
Journal Article
Closed access
SVSupraja G. Varadarajan
Supraja G. Varadarajan
JHJohn L. Hunyara
John L. Hunyara
NHNatalie R. Hamilton
Natalie R. Hamilton
AKAlex L. Kolodkin
Alex L. Kolodkin
AHAndrew D. Huberman
Andrew D. Huberman

1 December 2017 in Neuron
Verified
Journal Article
Closed access
QWQiang Wang
Qiang Wang
SCShu-Ling Chiu
Shu-Ling Chiu
EKEleftheria Koropouli
Eleftheria Koropouli
IHIngie Hong
Ingie Hong
SMSarah Mitchell
Sarah Mitchell
AKAlex L. Kolodkin
Alex L. Kolodkin

4 September 2025 in Ophthalmology Glaucoma
Verified
Journal Article
Open access
NHNatalie R. Hamilton
Natalie R. Hamilton
AAAnam Akhlaq
Anam Akhlaq
PNPatrick O. Nnoromele
Patrick O. Nnoromele
NGNicolas Gasquet
Nicolas Gasquet
CGCatalina Garzon
Catalina Garzon
TJThomas Johnson
Thomas Johnson
To assess the clinical outcomes of Hydrus Microstent implantation with cataract extraction for the treatment of open angle glaucoma (OAG) over a maximum of 4 years. Retrospective, single-center, single-arm, longitudinal cohort study. 308 patients (464 eyes) with OAG who underwent Hydrus Microstent implantation with cataract extraction between February 2019 and December 2021, followed for a median (interquartile range, IQR) of 2.0 (1.3, 2.8) years. Medical records were reviewed to collect demographic and clinical data. After assessment for Gaussian distribution, mean and standard deviation (SD) or median and IQR were calculated. Change from baseline was calculated with mixed-effects models and expressed as mean change and standard error (SE). 1) Intraocular pressure (IOP); 2) number of glaucoma medications; 3) need for additional glaucoma procedures; and 4) rate of glaucoma progression, calculated using mean deviation (MD) from standard automated perimetry and optical coherence tomography peripapillary retinal nerve fiber layer (RFNL) thickness. Among 308 patients, 60.7% (n=187) were White and 50.6% (n=156) were female. The median (IQR) age was 74 (68, 78) years. Most eyes had mild (63.8%) or moderate (23.9%) OAG. Of 464 eyes, 99 (21.4%) had undergone prior procedures for glaucoma. At baseline, the mean (±SD) IOP was 16.0±3.7 mmHg while taking 1.9±1.1 glaucoma medications. After Hydrus implantation, a sustained reduction was observed in mean IOP [mean change±SE]: -1.9±0.3 at 6 months (p<0.0001), -1.2±0.2 at 1 year (p<0.0001), -1.2±0.2 at 2 years (p<0.0001), -1.6±0.3 at 3 years (p<0.0001) and -1.2±0.7 at 4 years (p=0.02)]. Glaucoma medications were reduced by 1.2±0.1 at 6 months (p<0.0001), 1.1±0.1 at 1 year (p<0.0001), 1.0±0.1 at 2 years (p<0.0001), 0.9±0.1 at 3 years (p<0.0001) and 0.5±0.2 at 4 years (p=0.03). Only 14 eyes (3.2%) required additional glaucoma procedures. Compared to the lookback period, the rates of visual field MD and RNFL loss decreased in the postoperative period by 0.18±0.08 dB/year (-0.18±0.02 vs 0.004±0.08 dB/year, p=0.02) and 0.51±0.29 μm/year (-0.47±0.12 vs 0.04±0.21 μm/year, p=0.07), respectively. In this non-trial setting, cataract surgery with Hydrus Microstent implantation was associated with sustained reductions in IOP, glaucoma medication burden, and disease progression rate.

19 May 2026 in Ophthalmology Glaucoma
Verified
Journal Article
Open access
JSJasdeep Sabharwal
Jasdeep Sabharwal
MTMargaret Tharp
Margaret Tharp
NHNatalie Hamilton
Natalie Hamilton
YNYulia Nam
Yulia Nam
MPMaria Catalina Pizarro Penaranda
Maria Catalina Pizarro Penaranda
TJThomas Johnson
Thomas Johnson
To characterize the time to maximum intraocular pressure (IOP) change after stopping and restarting topical prostaglandin analog (PGA) treatment using remote tonometry. Prospective single-site observational study. Patients with primary open-angle glaucoma or ocular hypertension treated with ≥ 4 weeks of PGA monotherapy, in whom the managing ophthalmologist ordered medication washout to assess the necessity of continued topical therapy. Patients used a rebound home tonometer to obtain ≥4 daily measurements across 3 periods: "Baseline" (1 week while continuing PGA), "Washout" (4 weeks off therapy), and "Restart" (4 weeks while restarting PGA). Exponential decay functions were used to model IOP from "Baseline" through "Washout" and then from end of "Washout" through "Restart" to determine the time to 90% of maximum IOP change (plateau, T90%%). We evaluated the variation in T90% using multilevel models to account for the inclusion of both eyes from individual subjects. T90% for "Washout" and "Restart" RESULTS: 20 subjects (34 eyes) successfully recorded multiple daily eye measurements for the 9-week study period. Mean (SD) IOPs during the "Baseline", "Washout", and "Restart" periods were 15.6 (4.2) mmHg, 17.3 (5.0) mmHg, and 15.9 (4.4) mmHg, respectively. "Baseline" and "Restart" IOPs were significantly lower than "Washout" IOP (p < 0.001). T90% was significantly longer and more variable among subjects during Washout (median: 18.5 days; IQR 6.0-32.1 days) compared to Restart (2.2 days; 1.3-4.1 days, p < 0.001). Using remote tonometry, we identified a significantly longer T90% after stopping PGA drops than when they were restarted. The ranges of time to reach the IOP plateau were wide, often exceeding the standardized 4-week washout, and are relevant to clinical assessment of routine treatment effects and determination of accurate washout periods for clinical research studies.

3 November 2026 in Ophthalmology
Verified
Journal Article
Open access
MJMichael Seth Jensen
Michael Seth Jensen
ARAndy W. Renschler
Andy W. Renschler
CJCatherine Johnson
Catherine Johnson
CSCoy M. Steel
Coy M. Steel
DEDevin Eddington
Devin Eddington
BWBarbara M. Wirostko
Barbara M. Wirostko